GETUG-AFU 18.🇫🇷 80 Gy with LT-ADT, NEW standard of care in high-risk prostate cancer? Hennequin Christophe GETUG Association Française d'Urologie - AFU #Gu2024 #Gu24 #SanFrancisco

⚡️ Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a U.S. FDA pooled analysis #KidneyCancer #Immunotherapy buff.ly/4cygdWQ

A very innovative approach and happy to see the greatest Ian Davis (Bluesky @profiand) involved on it!!!! 👏👏👏👏 Sub-urothelial injection of durvalumab OncoAlert

Serial ctDNA testing from IMVIGOR11 (post cystectomy in muscle invasive bladder cancer) show that ctDNA-ve patients (n=171) with a minimum of 12months follow up have 10% relapse rates and almost no deaths #EAU24. Do we need to give adjuvant therapy to those as such low risk?

🔥🚨OncoAlert Hot Off the Press BIG NEWS Press Release by AstraZeneca #ADRIATIC phase 3 trial of #Durvalumab vs #Placebo after concurrent chemoradiotherapy in pts with limited-stage #SmallCell #LungCancer met dual primary endpoints of ⬆️#OS & ⬆️#PFS 👇🏼 astrazeneca.com/media-centre/p…

With Matt Galsky #EAU24 adjuvant nivolumab in bladder ca: HR 0.76 in ITT & 0.56 in PD-L1 +ve. Clinically meaningful results especially in PD-L1 +ves. No data on PD-L1-ve! OS is not yet significant but this data is impressive. ~60% relapse and 24% get subsequent IO. ~10% ⬆️tox.

Why rush radiotherapy after prostate surgery? ☢️RADICALS-RT trial shows waiting for PSA rise before radiotherapy could be the smarter move – fewer side effects without compromising cancer control. A potential game-changer for post-surgery treatment. #ProstateCancer Matt Sydes

New data from EV302 Enfortumab Vedotin & pembrolizumab for upper tract disease (~25% of pts). UTUC has distinct biological features including more FGFR alterations. PFS & OS HR of 0.50 & 0.53 respectively in the subset is in line with the whole population (0.45 and 0.47) #EAU24

Very pleased to see the interim results of #SURE01 trial [neoadj #sacituzumab govitecan prior to cystectomy in MIBC] slated for presentation at #ASCO24 | w preliminary bmk and bladder-saving results ASCO Journal of Clinical Oncology Antonio Cigliola Chiara Mercinelli Valentina Tateo Ospedale San Raffaele Università Vita-Salute San Raffaele

⚡️ Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial Jeremy Teoh #BladderCancer sciencedirect.com/science/articl…

very important news! Overall Survival seen in KN522!!!

Disappointing Results for Gilead’s Phase 3 TROPiCS-04 Study! ⭕️ Sacituzumab govitecan (Trodelvy) in metastatic urothelial cancer did not meet the primary endpoint of overall survival. ⭕️Increased deaths due to neutropenic complications were noted in the Trodelvy group. #Asco24

#LungSeries: This is the #Algorithm we have used during our discussion w/ @DrSteveMartin for mNSCLC w/ actionable mutations in 1L: - EGFR, ALK, ROS1, BRAF, NTRK, MET Econ 14, RET!!! #OncTwitter #MedTwtitter CancerNetwork® #lcsm

⚡️ On European Urology - Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection #BladderCancer Ashish M. Kamat, MD, MBBS sciencedirect.com/science/articl…

🔥A 9-year follow-up from the RADICALS-HD trial showed no significant difference in metastasis-free survival among prostate cancer patients receiving no ADT, 6-month ADT, or 24-month ADT after postoperative radiotherapy. ✅492 patients ✅10 years, 80% (no ADT), 77% (6-month

Tivozanib +/- nivolumab in IO pretreated M1 renal cancer showed retreatment with IO makes absolutely no difference. This is on top of CONTACT3 which showed the same thing.We need to stop retreating with IO.These data apply in the post adjuvant setting too without data #ESMO2024

SUNNIFORCAST #ESMO24 ipi/nivo vs VEGF based therapy in advanced non-clear cell renal cancer. +ve 12 month OS,OS HR 0.86, ⬆️RR but -ve PFS. Uncertainty around papillary subgroup & mixed control arm. But PD-1 based therapy looks like the backbone of future therapy. PD-L1 biomarker?

1/2🔥🚨OncoAlert Hot off the press. Just published Springer Nature #CurrentOncologyReports by our team Mayo Clinic Comprehensive Cancer Center A #Review Article on: ✅The #Antibody-#Drug #Conjugates (#ADCs) Therapeutic 💊#Revolution in #LungCancer 🫁(#NSCLC & #SCLC). 👇🏻 link.springer.com/article/10.100…

1/2 🫁 1st-line EGFR-TKIs 🫁 🫁 Summary of Clinical Data for EGFR-TKIs. 1st 2025. ⭐️ Only PFS & OS ⭐️ 3rd-generation Monotherapy

FDA APPROVAL EMRELIS™ (Telisotuzumab Vedotin) gets accelerated approval for advanced NSCLC with high c-MET protein overexpression! #LungCancer #NSCLC #FDA ✅ First ADC targeting MET (not a TKI!) 🧬 Targets protein overexpression (IHC 3+ in ≥50% cells), unlike other MET